ArticleScientific reports2024
Phage-antibiotic combinations to control Pseudomonas aeruginosa-Candida two-species biofilms.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 51 citations in OpenAlex.
- A Biological Approach to Antimicrobial Resistance in New and Old Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2026Review
- Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration.Archives of microbiology · 2026Review
- Fungal-Bacterial Interactions in Polymicrobial Infections: Hidden Threats.MicrobiologyOpen · 2026Review
- Rapid Evolution of Ionic Silver Resistance inMicroorganisms · 2026Article
- Article
- Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection.Nature microbiology · 2026Article
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- UnderstandingMicroorganisms · 2026Review
- Stepwise antibacterial strategy for orthopedic implants using bacteriophages on electrospun cefiderocol/PCl/Gt nanofibers over PEO-coated Mgnpj biomedical innovations · 2025Article
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
- Bacteriophages as an alternative strategy for the treatment of drug resistant bacterial infections: Current approaches and future perspectives.Cell surface (Amsterdam, Netherlands) · 2025Review
- Bacteriophage therapy to combat MDR non-fermenting Gram-negative bacteria causing nosocomial infections: recent progress and challenges.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Characterization of bacteriophages PAA and PAM and evaluation of their antibiotic synergy against Pseudomonas aeruginosa PAZMYU isolated from urine sample.BMC microbiology · 2025Article
- Synergistic Biocontrol ofInternational journal of molecular sciences · 2025Article
- Investigating the phenotypic alterations associated with hypermucoviscous hypervirulent Klebsiella pneumoniae during phage resistance development.BMC microbiology · 2025Article
- Augmenting phage therapy using green nanotechnology for promising infection control, wound healing and devoiding phage resistance in MDR Pseudomonas aeruginosa.Scientific reports · 2025Article
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- Combined Forces Against Bacteria: Phages and Antibiotics.Health science reports · 2025Article
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
- Novel therapeutic strategies targeting infections caused by P. aeruginosa biofilm.Molecular biology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage-antibiotic combinations to treat bacterial infections are gaining increased attention due to the synergistic effects often observed when applying both components together. Most studies however focus on a single pathogen, although in many clinical cases multiple species are present at the site of infection. The aim of this study was to investigate the anti-biofilm activity of phage-antibiotic/antifungal combinations on single- and dual-species biofilms formed by P. aeruginosa and the fungal pathogen Candida albicans. The Pseudomonas phage Motto in combination with ciprofloxacin had significant anti-biofilm activity. We then compared biofilms formed by P. aeruginosa alone with the dual-species biofilms formed by bacteria and C. albicans. Here, we found that the phage together with the antifungal fluconazole was active against 6-h-old dual-species biofilms but showed only negligible activity against 24-h-old biofilms. This study lays the first foundation for potential therapeutic approaches to treat co-infections caused by bacteria and fungi using phage-antibiotic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.